A New Model for the Identification of Frequent Hitters in HTS Data
HTS screening and analysis is an important part of the drug discovery process. Recognizing the importance of this data, Pfizer has created HTS models using several different methods throughout the last 20 years. Each iteration has aimed to improve the predictability of frequent hitters. Many of the models were built using a fraction of the data available. Using data from 8 million compounds, over 500 million data points and 1000 curated screens, we will show new methodology built off Pipeline Pilot Pilot to analyze a set of real as well as virtual compounds across Pfizer’s HTS data. 2022 BIOVIA Conference
